II
ENTA icon

Inspire Investing’s Enanta Pharmaceuticals ENTA Stock Holding History

Inspire Investing’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-14,743
Closed -$316K – 830
2023
Q2 		$316K Buy
14,743
+7,991
+118% +$236K 0.04% 460
2023
Q1 		$273K Buy
6,752
+1,615
+31% +$77.1K 0.03% 602
2022
Q4 		$239K Buy
5,137
+1,151
+29% +$52.5K 0.03% 364
2022
Q3 		$207K Sell
3,986
-510
-11% -$29.8K 0.03% 461
2022
Q2 		$213K Buy
4,496
+1,230
+38% +$66.8K 0.03% 410
2022
Q1 		$232K Sell
3,266
-142
-4% -$9.24K 0.03% 772
2021
Q4 		$255K Sell
3,408
-750
-18% -$58.9K 0.03% 344
2021
Q3 		$236K Buy
+4,158
New +$206K 0.03% 460
2021
Q2 		– Sell
-4,160
Closed -$205K – 599
2021
Q1 		$205K Sell
4,160
-1,110
-21% -$55.4K 0.03% 590
2020
Q4 		$222K Buy
+5,270
New +$232K 0.05% 588
2020
Q3 		– Sell
-4,712
Closed -$237K – 470
2020
Q2 		$237K Buy
4,712
+103
+2% +$5.33K 0.08% 319
2020
Q1 		$237K Buy
+4,609
New +$246K 0.09% 306

Other funds holding ENTA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Inspire Investing's ENTA Position: Q3 2023 in Review

Inspire Investing sold out of Enanta Pharmaceuticals (ENTA) in Q3 2023, closing a stake of 14,743 shares — an estimated $316K sold.

Inspire Investing first reported a position in ENTA in Q1 2020 and held it in 12 quarters. The position peaked at $316K in Q2 2023. 132 funds tracked by Wall St. Rank hold ENTA as of Q3 2023.

  • Inspire Investing reported no remaining Enanta Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Inspire Investing sold 14,743 Enanta Pharmaceuticals shares in Q3 2023, an estimated $316K.
  • Inspire Investing first reported a position in Enanta Pharmaceuticals in Q1 2020 and held it in 12 quarters.
  • Inspire Investing's Enanta Pharmaceuticals position peaked at $316K in Q2 2023.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2023.

Based on Inspire Investing's 13F filing for Q3 2023, filed 26 Oct 2023.